Gastric Cancer and gastroesophageal junction (GEJ) cancer frequently present as advanced disease. Although second-line treatment options are available, many patients with metastatic or advanced gastric cancer are not treated beyond first-line therapy in the real-world setting. The adoption of an evidence-based approach to treatment of advanced gastric and GEJ cancer is needed in order to optimize the integration of new targeted therapies across all lines of treatment.
The development of novel therapies has largely been driven by the integration of new molecular and clinical data, allowing researchers and clinicians to better characterize gastric tumors and identify prognostic and predictive biomarkers that aid in treatment selection. In this Clinical Toolkit, you will find recent treatment guidelines, clinical trial data on novel therapies, and research on biomarkers that impact treatment selection. A list of additional resources is provided to help improve the clinical outcomes of patients with gastric and GEJ cancer.